Coleman RL - Search Results

1

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Coleman RL, et al. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. N Engl J Med. 2019. PMID: 31722153 Free PMC article. Clinical Trial.

2

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.

Munkarah AR, Coleman RL. Munkarah AR, et al. Among authors: coleman rl. Gynecol Oncol. 2004 Nov;95(2):273-80. doi: 10.1016/j.ygyno.2004.09.018. Gynecol Oncol. 2004. PMID: 15491746 Review.

3

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Bhoola SM, et al. Among authors: coleman rl. Gynecol Oncol. 2004 Dec;95(3):564-9. doi: 10.1016/j.ygyno.2004.08.026. Gynecol Oncol. 2004. PMID: 15581964

4

Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.

Fujiwara K, Markman M, Morgan M, Coleman RL. Fujiwara K, et al. Among authors: coleman rl. Gynecol Oncol. 2005 Apr;97(1):10-5. doi: 10.1016/j.ygyno.2004.12.005. Gynecol Oncol. 2005. PMID: 15790431 Review.

5

Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.

Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Gallion H, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):194-201. doi: 10.1111/j.1525-1438.2006.00301.x. Int J Gynecol Cancer. 2006. PMID: 16445633

6

The role of maintenance therapy and novel taxanes in ovarian cancer.

Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. Herzog TJ, et al. Among authors: coleman rl. Gynecol Oncol. 2006 Aug;102(2):218-25. doi: 10.1016/j.ygyno.2005.12.001. Epub 2006 Feb 7. Gynecol Oncol. 2006. PMID: 16460787 Review.

7

A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.

Herzog TJ, Coleman RL, Guerrieri JP Jr, Gabriel K, Du W, Techner L, Fort JG, Wallin B. Herzog TJ, et al. Among authors: coleman rl. Am J Obstet Gynecol. 2006 Aug;195(2):445-53. doi: 10.1016/j.ajog.2006.01.039. Epub 2006 Apr 19. Am J Obstet Gynecol. 2006. PMID: 16626607 Clinical Trial.

8

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. Gossner G, et al. Among authors: coleman rl. Gynecol Oncol. 2006 Oct;103(1):212-8. doi: 10.1016/j.ygyno.2006.02.026. Epub 2006 May 3. Gynecol Oncol. 2006. PMID: 16677696

9

Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.

Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Coleman RL, et al. Oncologist. 2007 Jan;12(1):72-8. doi: 10.1634/theoncologist.12-1-72. Oncologist. 2007. PMID: 17227902 Free article. Clinical Trial.

10

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.

Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Crotzer DR, et al. Among authors: coleman rl. Gynecol Oncol. 2007 May;105(2):404-8. doi: 10.1016/j.ygyno.2006.12.024. Epub 2007 Feb 9. Gynecol Oncol. 2007. PMID: 17292461

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

609 results

Search Page

Filters